[ { "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2026", "title": "Kvartalsrapport Q2 2026", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a5fb4d9921ffc8f338e9eaa7b76e42b81", "date": "2026-08-05", "period": "2026-q2", "form_type": "interim-report", "report_key": "2026:q2", "filename": "Xspray_Pharma_delarsrapport_Q2_2026.pdf", "text_chars": 47343, "sha256": "02f3f4381a8341b276240e25960e35d4230f48dc2aae298f92712946fc4ef5a6", "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026", "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026", "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026/fulltext.txt", "parts": [ { "number": 1, "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026/part-001.html", "chars": 47343 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026", "title": "Kvartalsrapport Q1 2026", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/afbf18fcb4e6880f16937b1dc4ce42b76", "date": "2026-04-28", "period": "2026-q1", "form_type": "interim-report", "report_key": "2026:q1", "filename": "20260428_Xspray_Pharma_Q1_2026_SWE.pdf", "text_chars": 40730, "sha256": "6354e9b871d541856b0eba87fe93ab69eebd9278f587c7992d5501d2c03976fb", "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026", "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026", "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt", "parts": [ { "number": 1, "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html", "chars": 40730 } ] }, { "doc_id": "nasdaq-nordic-arsredovisning-2025", "title": "Årsredovisning 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/ae01aee44e2723ff4457afdfae84de95c", "date": "2026-03-26", "period": "2025-annual", "form_type": "annual-report", "report_key": "2025:annual", "filename": "20260326_Xspray_Pharma_Arsredovisning_2025_Sv.pdf", "text_chars": 266519, "sha256": "2f45693c0c8e592933453650e9e5f992a05d12a66cc8101993adab71c53e431e", "url": "/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2025", "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2025", "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2025/part-001.html", "chars": 173042 }, { "number": 2, "url": "/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2025/part-002.html", "chars": 93475 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025", "title": "Kvartalsrapport Q4 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a2085b761e4cf1e849faa1eb4bbbeaa26", "date": "2026-02-12", "period": "2025-q4", "form_type": "year-end-report", "report_key": "2025:q4", "filename": "20260212_Xspray_Pharma_Q4_2025_SWE.pdf", "text_chars": 42171, "sha256": "2d4e02ef3a6c68654bd187d34c08d60d376f55836f554aae4d8fd660856b7645", "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025", "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025", "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html", "chars": 42171 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025", "title": "Kvartalsrapport Q3 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a2973552cc28b15c2dfd57999d37e8ebe", "date": "2025-11-05", "period": "2025-q3", "form_type": "interim-report", "report_key": "2025:q3", "filename": "20251105_Xspray_Q3_2025_SWE.pdf", "text_chars": 49592, "sha256": "8e1bca1d6c9eca51bf5afc23f5f4699d6aebafa0fde8c9ff5a2674ae28d8cd02", "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025", "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025", "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html", "chars": 49592 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025", "title": "Kvartalsrapport Q2 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a00d7f6790743fd3f21c1481d099647e3", "date": "2025-08-15", "period": "2025-q2", "form_type": "interim-report", "report_key": "2025:q2", "filename": "20250815_Q2_2025_Xspray_Pharma_Sv.pdf", "text_chars": 44959, "sha256": "22ade9dbe1298fd5338335e2aa5165d910c5593b240977b15393bf153ae7bc49", "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025", "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025", "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html", "chars": 44959 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025", "title": "Kvartalsrapport Q1 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/ae59b311919077480cf5001cb869af7bb", "date": "2025-05-07", "period": "2025-q1", "form_type": "interim-report", "report_key": "2025:q1", "filename": "20250507_Xspray_Pharma_Q1_2025_SWE.pdf", "text_chars": 37760, "sha256": "e039b8905a6bcd363ac7fccae066eb64a978314a6a7a04845265de116a2e6093", "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025", "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025", "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html", "chars": 37760 } ] }, { "doc_id": "nasdaq-nordic-arsredovisning-2024", "title": "Årsredovisning 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/ad983d0ddc1684674f58fc36133dc6082", "date": "2025-03-27", "period": "2024-annual", "form_type": "annual-report", "report_key": "2024:annual", "filename": "20250327_Xspray_Arsredovisning_2024_Sv.pdf", "text_chars": 248500, "sha256": "706f93b3b3ba44a8ef5dd4c2ba85689608b03cf91c8b2f742cad483acedb41d3", "url": "/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2024", "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2024", "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2024/part-001.html", "chars": 179367 }, { "number": 2, "url": "/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2024/part-002.html", "chars": 69131 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024", "title": "Kvartalsrapport Q4 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/ac0d2e0c82f48999bc87eaef7f68bc17f", "date": "2025-02-12", "period": "2024-q4", "form_type": "year-end-report", "report_key": "2024:q4", "filename": "20250212_Xspray_Pharma_Q4_2024_SWE.pdf", "text_chars": 42996, "sha256": "ce72ee6a9107d2a9d2c5632fcd774ec9a32049f529807ef35e7cb0df90ef5858", "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024", "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024", "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html", "chars": 42996 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024", "title": "Kvartalsrapport Q3 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a95f135cd65eb2de4cd562a7765280325", "date": "2024-11-06", "period": "2024-q3", "form_type": "interim-report", "report_key": "2024:q3", "filename": "20241106_Xspray_Q3_2024_SWE.pdf", "text_chars": 52179, "sha256": "999635d16ff274d2a309dfbbb1c11fd1df287aa8e5acbe8a8eb820e96aa4f6be", "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024", "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024", "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html", "chars": 52179 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024", "title": "Kvartalsrapport Q2 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/ad0827b50527699a23f334ff8952dd66d", "date": "2024-08-07", "period": "2024-q2", "form_type": "interim-report", "report_key": "2024:q2", "filename": "20240807_Xspray_Q2_2024_SWE.pdf", "text_chars": 44933, "sha256": "a6a3cf1b14ed8c151100b86619225f73bc2624eb47761beb82eb8c10bd3e764c", "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024", "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024", "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html", "chars": 44933 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024", "title": "Kvartalsrapport Q1 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/ae427f3bc7ac305abb40e57c5e2b0d750", "date": "2024-05-08", "period": "2024-q1", "form_type": "interim-report", "report_key": "2024:q1", "filename": "20240508_Xspray_Pharma_Q1_2024_Rapport_Sv.pdf", "text_chars": 40316, "sha256": "17e047cbc2fa02bba9510944f39e37cb24867cbfeb9a05888688fc7818f606fb", "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024", "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024", "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html", "chars": 40316 } ] }, { "doc_id": "nasdaq-nordic-arsredovisning-2023", "title": "Årsredovisning 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/ad9fd8db8f5736fc5fabd195c1072b922", "date": "2024-03-27", "period": "2023-annual", "form_type": "annual-report", "report_key": "2023:annual", "filename": "20240327_Xspray_Pharma_Arsredovisning_2023_Sv.pdf", "text_chars": 247137, "sha256": "57da7d7a02646ea2eefe2f61c826a6b3e6635b9ba76fc6c95a33291ce513d650", "url": "/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2023", "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2023", "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2023/part-001.html", "chars": 179074 }, { "number": 2, "url": "/company/xspray-pharma/documents/nasdaq-nordic-arsredovisning-2023/part-002.html", "chars": 68061 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023", "title": "Kvartalsrapport Q4 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a140a716efe18f1eb185d46b153d16935", "date": "2024-02-14", "period": "2023-q4", "form_type": "year-end-report", "report_key": "2023:q4", "filename": "2024_02_14_XsprayPharma_Q4_Rapport_SWE.pdf", "text_chars": 45285, "sha256": "ee901f87fdb52b52194f01ea087543f9f618c13c5bb010140dcb8d328b0d60b3", "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023", "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023", "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html", "chars": 45285 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023", "title": "Kvartalsrapport Q3 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a92ea5449e715c9e54884b6eb64ddabd4", "date": "2023-11-08", "period": "2023-q3", "form_type": "interim-report", "report_key": "2023:q3", "filename": "20231108_Xspray_Pharma_Q3_2023_Rapport_SWE.pdf", "text_chars": 48050, "sha256": "f61c4d7618408aa09df8cd67ed266e4d4648ce31270bddc9fda8960fe66d43e7", "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023", "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023", "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html", "chars": 48050 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023", "title": "Kvartalsrapport Q2 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/ae3558d64f63ccbf7c7ada0c7ccbf2557", "date": "2023-08-02", "period": "2023-q2", "form_type": "interim-report", "report_key": "2023:q2", "filename": "Xspray_Q2_Rapport_SWE.pdf", "text_chars": 43237, "sha256": "46f070043e9ca848d42fa0b69b0b0ce8d442f436ec7f568c31599d110c2237d7", "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023", "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023", "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html", "chars": 43237 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023", "title": "Kvartalsrapport Q1 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/abca29c48cc1571e3bd7eaf6682e27ba1", "date": "2023-05-04", "period": "2023-q1", "form_type": "interim-report", "report_key": "2023:q1", "filename": "20230504_Xspray_Pharma_Q1_2023_SWE.pdf", "text_chars": 41483, "sha256": "5233c3df9bbc521cb373ca446c0c759309e5d7b037b0a536b78cbfd48ca49c6f", "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023", "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023", "txt_url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/xspray-pharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html", "chars": 41483 } ] }, { "doc_id": "mfn-mfn-bolagssida-och-bolagsmetadata", "title": "MFN bolagssida och bolagsmetadata", "source": "MFN", "source_class": "mfn", "source_url": "https://mfn.se/all/a/xspray-pharma", "date": null, "period": null, "form_type": "company-page", "report_key": null, "filename": "company.txt", "text_chars": 12882, "sha256": "27214fc8323352244a118540568531cf7f29be4ec9075f86f33df4602aab8388", "url": "/company/xspray-pharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata", "absolute_url": "https://spela.port0.org/company/xspray-pharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata", "txt_url": "/company/xspray-pharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/xspray-pharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt", "parts": [ { "number": 1, "url": "/company/xspray-pharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata/part-001.html", "chars": 12882 } ] } ]